<div><div></div><div><span><p><strong><span>InMed reported a Q3 fiscal 2026 net loss of $3.0 million and cash, cash equivalents and short‑term investments of $5.2 million while INM-901 showed anti‑neuroinflammatory effects in human 3D brain organoids.</span></strong></p><p><strong><span>Key Highlights:</span></strong></p><ul><li><span>Q3 (ended Mar 31, 2026) net loss of $3.0M vs $2.1M year‑ago; increase driven by higher R&amp;D and financing costs.</span></li><li><span>Cash, cash equivalents and short‑term investments totaled $5.2M as of Mar 31, 2026 (down from $10.8M on Jun 30, 2025).</span></li><li><span>INM-901 preclinical data in two human 3D brain organoid models showed dose‑dependent reductions in IL‑6 and IL‑8.</span></li><li><span>Anti‑inflammatory effects of INM-901 are consistent with prior in vivo and ex vivo findings, supporting translational potential.</span></li><li><span>BayMedica commercial operations classified as discontinued; wind down expected substantially complete by June 30, 2026.</span></li></ul><p><span>Original SEC Filing: </span>InMed Pharmaceuticals Inc. [ INM ] - 8-K - May. 06, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

LABU

<p>InMed Pharmaceuticals reported a Q3 FY2026 net loss of $3.0 million, an increase from $2.1 million year-over-year, attributed to higher R&D and financing costs. The company has $5.2 million in cash and short-term investments, down from $10.8 million in June 2025. INM-901 demonstrated anti-neuroinflammatory effects in human 3D brain organoids, showing promise for future applications. Additionally, BayMedica's commercial operations are being discontinued, with a wind-down expected by June 30, 2026.</p>

TradingView

InMed Pharmaceuticals

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

InMed Reports Q3 FY2026: Net Loss $3.0M, Cash $5.2M, INM-901 shows human organoid anti‑inflammatory effects